Cipriani, A, Zhou, X, Del Giovane, C, Hetrick, SE, Qin, B, Whittington, C, et al.
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: A network meta-analysis. Lancet
2016; 388(10047): 881–90.
Jureidini, J. Antidepressants fail, but no cause for therapeutic gloom. Lancet
2016; 388(10047): 844–5.
Weisz, JR, Kuppens, S, Ng, MY, Eckshtain, D, Ugueto, AM, Vaughn-Coaxum, R, et al.
What five decades of research tells us about the effects of youth psychological therapy: A multilevel meta-analysis and implications for science and practice. Am Psychol
2017; 72(2): 79–117.
March, J, Silva, S, Petrycki, S, Curry, J, Wells, K, Fairbank, J, et al.
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA
2004; 292(7): 807–20.
Bridge, JA, Iyengar, S, Salary, CB, Barbe, RP, Birmaher, B, Pincus, HA, et al.
Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials. JAMA
2007; 297(15): 1683–96.
Bridge, JA, Birmaher, B, Iyengar, S, Barbe, RP, Brent, DA. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry
2009; 166(1): 42–9.
Furukawa, TA, Cipriani, A, Atkinson, LZ, Leucht, S, Ogawa, Y, Takeshima, N, et al.
Placebo response rates in antidepressant trials: A systematic review of published and unpublished double-blind randomised controlled studies. Lancet Psychiatry
2016; 3(11): 1059–66.
Leucht, S, Leucht, C, Huhn, M, Chaimani, A, Mavridis, D, Helfer, B, et al.
Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry
2017; 174(10): 927–42.
Gibbons, RD, Hur, K, Brown, CH, Davis, JM, Mann, JJ. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry
2012; 69(6): 572–9.
Hazell, P, O'Connell, D, Heathcote, D, Robertson, J, Henry, D. Efficacy of tricyclic drugs in treating child and adolescent depression: A meta-analysis. BMJ
1995; 310(6984): 897–901.
Brent, DA, Emslie, GJ, Clarke, GN, Asarnow, J, Spirito, A, Ritz, L, et al.
Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry
2009; 166(4): 418–26.
Atkinson, SD, Prakash, A, Zhang, Q, Pangallo, BA, Bangs, ME, Emslie, GJ, et al.
A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol
2014; 24(4): 180–9.
Simon, GE, Savarino, J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry
2007; 164(7): 1029–34.
Gibbons, RD, Hur, K, Bhaumik, DK, Mann, JJ. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry
2006; 163(11): 1898–904.
Gibbons, RD, Hur, K, Bhaumik, DK, Mann, JJ. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry
2005; 62(2): 165–72.
Ludwig, J, Marcotte, DE, Norberg, K. Anti-depressants and suicide. J Health Econ
2009; 28(3): 659–76.
Gibbons, RD, Brown, CH, Hur, K, Marcus, SM, Bhaumik, DK, Erkens, JA, et al.
Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry
2007; 164(9): 1356–63.
Katz, LY, Kozyrskyj, AL, Prior, HJ, Enns, MW, Cox, BJ, Sareen, J. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. CMAJ
2008; 178(8): 1005–11.
Vitiello, B, Rohde, P, Silva, S, Wells, K, Casat, C, Waslick, B, et al.
Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry
2006; 45(12): 1419–26.
Emslie, G, Kratochvil, C, Vitiello, B, Silva, S, Mayes, T, McNulty, S, et al.
Treatment for Adolescents with Depression Study (TADS): Safety results. J Am Acad Child Adolesc Psychiatry
2006; 45(12): 1440–55.
March, JS, Silva, S, Petrycki, S, Curry, J, Wells, K, Fairbank, J, et al.
The Treatment for Adolescents With Depression Study (TADS): Long-term effectiveness and safety outcomes. Arch Gen Psychiatry
2007; 64(10): 1132–43.
Brent, DA, Holder, D, Kolko, D, Birmaher, B, Baugher, M, Roth, C, et al.
A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Arch Gen Psychiatry
1997; 54(9): 877–85.
Hopkins, K, Crosland, P, Elliott, N, Bewley, S. Diagnosis and management of depression in children and young people: Summary of updated NICE guidance. BMJ
2015; 350: h824.
Brent, D, Emslie, G, Clarke, G, Wagner, KD, Asarnow, JR, Keller, M, et al.
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: The TORDIA randomized controlled trial. JAMA
2008; 299(8): 901–13.
Curry, J, Rohde, P, Simons, A, Silva, S, Vitiello, B, Kratochvil, C, et al.
Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry
2006; 45(12): 1427–39.
Vitiello, B, Emslie, G, Clarke, G, Wagner, KD, Asarnow, JR, Keller, MB, et al.
Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: A follow-up study of the TORDIA sample. J Clin Psychiatry
2011; 72(3): 388–96.
Walkup, JT. Antidepressant efficacy for depression in children and adolescents: Industry- and NIMH-funded studies. Am J Psychiatry
2017; 174(5): 430–7.
Thurber, J. Lanterns & Lances: New York: Harper; 1961: xv.